Factories Get Smarter, Seas Stay Steady, and Dilution Sends a Chill

One diagnostics player surged after striking a manufacturing deal that promises big cost savings and production gains, while a long-awaited FDA approval boosted sentiment in motion-related treatment. But elsewhere, dilution worries tied to fresh funding mechanics kept pressure on one recent high-flyer.

Here’s what all that means for you.

Amazon (AMZN) may have just cracked the AI power code and solved this country’s energy problems... Jeff Bezos just doubled down on a breakthrough tech that's fast-tracking a $40 trillion industry.

This is still flying under the radar, but it won’t be long before this is mainstream news.

Find out how you can prepare and invest before everyone else right here.

U.S. stocks slipped as thin year-end trading and caution over the Fed’s December minutes weighed on sentiment, with investors also taking profits after a strong year.

DigitalBridge Group, Inc. (NYSE: DBRG) just made a move that signals a shift in how it wants to grow.

By taking a major U.S. fiber broadband provider private, the firm is moving closer to the physical backbone of the digital economy rather than sitting one step removed as a capital allocator.

This is not about financial engineering. It is about control, scale, and long-term infrastructure ownership in a world that keeps demanding more bandwidth.

Why Fiber Is the Real Prize

Fiber is no longer a niche utility. It is core infrastructure for cloud computing, streaming, remote work, AI workloads, and data-heavy businesses.

Owning and modernizing these networks creates steady cash flows while positioning DigitalBridge at the center of how digital demand actually moves.

By expanding fiber deployments and accelerating network upgrades, the company strengthens its exposure to assets that grow with usage rather than consumer cycles.

That shift puts you closer to a business model built on steady demand instead of short-term swings.

The Strategic Reset Inside DigitalBridge

This deal reshapes DigitalBridge into a more hands-on operator with a deeper reach across digital infrastructure.

It adds another lever beyond towers, data centers, and small cells, tightening the ecosystem around connectivity itself.

Private ownership also allows faster decision-making, longer investment horizons, and heavier upfront spending without quarterly noise.

That flexibility matters in infrastructure where returns compound over years, not months.

AbbVie (NYSE: ABBV) has secured a new global oncology option through a collaboration with Zelgen Pharma, adding ZG006, also known as Alveltamig, to its pipeline outside Greater China.

This is not a regional play or a marketing tie-up. It is a deliberate expansion of AbbVie’s future cancer toolkit.

Under the agreement, AbbVie controls development and commercialization globally, while Zelgen keeps rights in mainland China, Hong Kong, and Macau.

When you look at the structure, it is designed for flexibility first, not hype.

A Deal Built for Proof, Not Promises

AbbVie paid $100 million upfront and structured the rest around milestones and a license option. That keeps risk contained while preserving upside if the science delivers.

Instead of overpaying early, AbbVie waits for data. If ZG006 performs, you see full global control unlock step by step rather than all at once.

Oncology Depth Without the Mega Bet

ZG006 adds a next-generation immune-based therapy at a time when differentiated oncology assets are scarce and expensive.

The program is designed for broader tumor use and future combinations, which fits neatly with AbbVie’s existing cancer portfolio.

This is also about geography. By pulling innovation from multiple regions, AbbVie keeps its pipeline flexible and competitive.

Put you in the middle of that strategy, and it becomes clear the company is not chasing noise; it is building depth. 

If this asset delivers, you are standing in front of a global franchise that was assembled quietly and deliberately, not rushed or overpaid.

The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous.

He says it's about to change everything you know about money.

Full story here. 

Kroger (NYSE: KR) is heading into 2026 with a very different posture after putting its highly anticipated Albertsons (ACI) failed merger attempt behind it.

The focus now is not scale for the sake of headlines, but execution, cash discipline, and winning the weekly grocery trip in a tougher consumer environment.

This reset shows up in how the company is simplifying decisions.

Kroger is leaning into core grocery demand, private label strength, and pricing discipline, the things that work when budgets are tight, and habits matter.

Execution Replaces Big Bets

Kroger has taken a hard look at parts of its automated fulfillment strategy and cleared out underperforming investments.

That clean up matters because it frees capital and attention for stores, supply reliability, and everyday convenience.

Instead of chasing experimental scale, the company is choosing consistency.

When you walk into a Kroger, the goal is availability, value, and familiarity, not flashy tech that does not pay off.

Digital Gets Grounded

Online grocery still matters, but the strategy has changed. Kroger is prioritizing efficiency and profitability, so digital supports stores instead of dragging margins.

The message is clear. Kroger is done chasing transformative stories.

It is rebuilding around predictability, cash durability, and execution, and if you are watching food retail closely, that kind of focus tends to show up where it counts most, in steady results and customer habits.

👉 Click here to get our closing report to your cell for free!

Intelligent Bio Solutions [INBS] $9.60 (+134.15%)

Intelligent Bio Solutions jumped after striking a strategic manufacturing deal expected to cut production costs by more than 40% and significantly expand capacity for its fingerprint drug-screening reader.

Vanda Pharmaceuticals [VNDA] $8.82 (+25.46%)

Vanda jumped after the FDA approved its motion-sickness drug Nereus, the first new pharmacologic treatment for the condition in more than 40 years.

Axsome Therapeutics [AXSM] $182.88 (+22.91%)

Axsome rose after the FDA granted Priority Review to AXS-05 for Alzheimer’s agitation and also signaled that the company’s data package is sufficient to file an NDA for AXS-12 in narcolepsy.

SMX Public Limited Company [SMX] $16.35 (-68.22%)

SMX fell as investors reacted to an SEC filing detailing share registrations tied to convertible notes and an equity line of credit, increasing dilution concerns after a steep prior-day selloff.

Corcept Therapeutics [CORT] $34.81 (-50.41%)

Corcept plunged after the FDA declined to approve its drug relacorilant for hypertension linked to Cushing’s syndrome, saying more evidence of effectiveness is needed.

Ekso Bionics Holdings [EKSO] $8.64 (-18.34%)

Ekso Bionics fell after HC Wainwright downgraded the stock from Buy to Neutral, signaling a more cautious outlook following a sharp recent rally.

They mocked your values and expected everyday Americans to stay financially exposed.

Now the dollar faces pressure, global conflicts threaten stability, and inflation quietly eats away at savings.

Doing nothing is exactly what powerful interests are counting on as uncertainty grows.

This Patriot’s Tax Shield explains how real, physical gold can help defend wealth during political and economic disruption.

A free Wealth Protection Guide reveals how Trump’s agenda could impact gold and why timing matters now.

Click here to get the FREE Wealth Protection Guide now.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.